Changzhou Qianhong Biopharma CO.,LTD (SHE:002550)
China flag China · Delayed Price · Currency is CNY
6.15
-0.21 (-3.30%)
Nov 13, 2026, 3:04 PM CST

SHE:002550 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
230.73398.8356.03181.86323.41181.08
Depreciation & Amortization
64.5264.9765.4969.2264.7669.43
Other Amortization
5.294.844.393.753.555.67
Loss (Gain) From Sale of Assets
-0.01-0.01--25.35-57.59-
Asset Writedown & Restructuring Costs
0.10.10.047.770.240.46
Loss (Gain) From Sale of Investments
-18.14-18.14-13.89-8.833.82-0.64
Provision & Write-off of Bad Debts
-0.12-0.126.04-19.0215.3-52.68
Other Operating Activities
17.2-120.62-101.4819.11-46.626.11
Change in Accounts Receivable
-37.84-37.84-12.26420.4-165.955.37
Change in Inventory
49.0749.07172.11-77.46-136.12-84.79
Change in Accounts Payable
12.9212.9224.09-50.63-83.14-86.65
Change in Other Net Operating Assets
-2.09-2.09-0.621.984.374.12
Operating Cash Flow
331.12361.36514.71533.33-71.47103.56
Operating Cash Flow Growth
-6.81%-29.79%-3.49%---67.36%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-168.8-141.6-90.64-100.33-70.99-90.37
Sale of Property, Plant & Equipment
0.110.0913.532.30.110
Cash Acquisitions
-----1.67-
Investment in Securities
208.97208.97-232.15-108.5-121.08177.22
Other Investing Activities
-130.74-229.8-13.941.433.658.43
Investing Cash Flow
-90.46-162.34-323.23-175.1-189.9895.28

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Short-Term Debt Issued
--4.69435.51461.27124.95
Total Debt Issued
75.55-4.69435.51461.27124.95
Short-Term Debt Repaid
--20-40.1-480-440-77.43
Total Debt Repaid
--20-40.1-480-440-77.43
Net Debt Issued (Repaid)
75.55-20-35.41-44.4921.2747.52
Issuance of Common Stock
8.268.26--144.9-
Repurchase of Common Stock
---140.77-30.09--0.19
Common Dividends Paid
-189-150.43-151.52-158.79-155.16-151.51
Other Financing Activities
46.1324.5342.5--
Financing Cash Flow
-59.06-137.68-324.71-190.8711.02-104.17

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-18.73-13.05-1.85-1.641.897.39
Net Cash Flow
162.8648.29-135.07165.76-208.55102.06

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
162.31219.76424.07433-142.4613.19
Free Cash Flow Growth
-27.32%-48.18%-2.06%---94.82%
Free Cash Flow Margin
10.75%13.99%27.79%23.87%-6.18%0.70%
Free Cash Flow Per Share
0.130.180.330.33-0.110.01
Levered Free Cash Flow
146.31190.25332.89344.34-216.74-40.56
Unlevered Free Cash Flow
146.54190.54333.76348.04-213.46-39.53

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
45.03156.06150.6545.1626.5581.87
Change in Working Capital
31.5531.55198.09304.81-378.36-105.88